The following is a review of diagnostic product developments worldwideThe information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.
The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Product developments in February 2002
AcroMetrix Corp has introduced its Hepatitis C Virus (HCV) Genotyping Proficiency Program available to molecular diagnostics laboratories.
American Bio Medica Corp has entered into a distribution agreement for its Rapid Drug Screen testing system with Quest Diagnostics Incorporated. ABMC will be Quest Diagnostics' exclusive manufacturer of urine based Point-of-Collection drug-testing devices.
Bayer Diagnostics introduced its Multistix PRO Reagent Strips. The urine test strip uses a protein to creatinine ratio to significantly reduce false results.
Beckman Coulter, Inc. and Corixa Corporation have entered into a cross-licensing agreement. Corixa has granted Beckman Coulter a license to certain patented technology, which Beckman Coulter intends to use in the development of MHC Tetramers for autoimmune disease diagnostics. Corixa plans to use Tetramer technology in the discovery of therapies for cancer, infectious diseases and autoimmune diseases.
Beyond Genomics, Inc. and diaDexus, Inc. have entered into an agreement to apply Beyond Genomics' Systems Biology to identify new biomarkers and drug targets useful for the diagnosis and treatment of colon, breast and ovarian cancer.
Bio-Rad Laboratories Inc. has developed two new automated platforms for BSE testing. Bio-Rad is also introducing a second-generation BSE screening test, along with a Western Blot confirmation test.
Chiron Corporation and Gen-Probe have received FDA clearance to market the Procleix HIV-1/HCV Assay. The nucleic acid amplification test is designed to detect the presence of all known HIV-1 subtypes and HCV genotypes in whole blood.
Eprogen, Inc. has introduced ProteoSep technology for the identification of bacterial and viral strains. ProteoSep provides protein patterns of individual strains of bacteria that can be analyzed and graphically mapped to create detailed, unique fingerprints of the strain.
Genomic Profiling Systems is developing non-magnified digital imaging technologies for bacteria and virus analyses - Cell Direct for the detection of individual microbes; Growth Direct for the detection of microbial growth and MultiPath for the detection of multiple disparate targets, e.g., bacteria, viruses, and toxins.
IRIS has received FDA clearance to market Aution Max AX-4280 Automated Urine Analyzer manufactured by ARKRAY of Japan.
Medical Services International Inc. is developing the VScan Hepatitis C and Hepatitis B rapid POC test kits. VScan Test Kit can be used in doctor's offices, medical clinics, dialysis units, blood banks, emergency rooms and in the home for personal testing.
Meretek Diagnostics Inc. has received FDA clearance for the BreathTek-UBiT breath test kit for detection of active Helicobacter pylori infection. The kit is designed for use with the FDA cleared, POC UBiT-IR300 infra-red spectrophotometer.
Morewood Molecular Sciences, Inc and the Institute for Transfusion Medicine are developing a micro-array system that simultaneously assay hundreds of enzyme reactions for coagulation testing.
OraSure Technologies Inc. has announced that Quest Diagnostics, Inc. has signed an agreement to market Intercept, OraSure Technologies' oral fluid drug testing solution. Terms of the agreement were not disclosed.
Psychemedics Corporation has received FDA clearance for its test for the detection of methamphetamine and MDMA (Ecstasy) in human hair.
Sequella, Inc., is developing the Transdermal Patch for Active Tuberculosis, a skin test that can distinguish between active infectious TB, latent TB and prior TB vaccination. The patch is configured as a simple Band-Aid applied to the forearm that delivers a soluble TB protein directly to the skin.
Spectral Diagnostics has signed a non- exclusive agreement with Abbott Laboratories to provide Troponin I technology for use on Abbott's immunoassay systems.
Product developments - January 2002
Product Developments Worldwide | Research News | Health Care in Canada
Information Technology and Healthcare | Molecular Biology | Links
Send mail to email@example.com with questions or comments about this web site.
Concept and Design Blue Page
Last modified: March 01, 2002